Synaptogenix Inc (SNPX)

[InTheTrenches]

Things I'd like to see in this week's (July 25th) poster presentation:

- Blood markers: A direct correlation between increasing PKC-e and improving SIB scores.

- The percentage of non-memantine patients helped by Bryostatin. If most trial patients are helped, it means most moderate-to-severe AD patients will be eligible to receive Bryostatin.

- The range of improvement in SIB score in non-memantine pts. If the range of improvement in SIB scores is narrow and consistent, this indicates healthcare professionals administering Bryostatin won't have to individualize the treatment dose and schedule. Also, this gives greater confidence in the company requiring only 100 patients in the confirmatory trial.

- Further clarification on the reason for stratification by MMSE score (4-9, 10-15).